- This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian peptide medicines, with scalable options that meet a full range of product requirements.
OKLAHOMA CITY AND TORRANCE, Calif.–(BUSINESS WIRE)–In response to growing demand for peptide medicines, Cytovanse Biologics, Inc. and Polypeptide Corporation announce a partnership that combines Cytovanse's expertise in microbial and mammalian expression, process development and manufacturing cGMP with PolyPeptide. Capabilities in complex peptide development and manufacturing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113598664/en/
Axel Schleier, Chief Operating Officer of Cytovance Biologics: Cytovance has been supporting the development and expansion of microbial and mammalian biologics for two decades. Combining our strengths with PolyPeptide is exactly what our customers and the industry need to support rapid market demand.
Trishul Shah, Business Development Director, PolyPeptide: With a proven track record of over 1,000 therapeutic peptides synthesized, PolyPeptide offers deep peptide development and synthesis capabilities. This collaboration gives customers access to complementary technology portfolios to drive their innovative drug development projects.
The two companies have previously collaborated on specific projects for clients. The new collaboration expands the partnership to benefit drug developers looking for additional capacity, rapid scale-up, and increased efficiency, helping to propel new peptide products into the clinic and market.
View source version on Businesswire.com: https://www.businesswire.com/news/home/20250113598664/en/
For media inquiries regarding Cytovance, please contact:
media@elementcg.co
@Cytovance Biologics “Follow us LinkedIn
For media inquiries about polypeptides, please contact:
mediateam@polypeptide.com
@PolyPeptide Follow us LinkedIn
Source: Cytovanse Biologicals
